# The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction

> **NCT07381803** · PHASE3 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 2804 (estimated)

## Conditions studied

- Zhejiang University

## Interventions

- **DRUG:** Fexofenadine 60 Mg Oral Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07381803
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-27
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 2804 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07381803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07381803, "The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07381803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*